MD Anderson Cancer: Combination Targeted Therapy Provides Durable Remission for Patients With Chronic Lymphocytic Leukemia
June 11, 2021
June 11, 2021
HOUSTON, Texas, June 11 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up dat . . .
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up dat . . .